Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $785.60 million. The enterprise value is $502.60 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ELVN has 49.07 million shares outstanding. The number of shares has increased by 18.45% in one year.
Current Share Class | 49.07M |
Shares Outstanding | 49.07M |
Shares Change (YoY) | +18.45% |
Shares Change (QoQ) | +0.39% |
Owned by Insiders (%) | 5.37% |
Owned by Institutions (%) | 63.02% |
Float | 26.57M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.72 |
P/TBV Ratio | 2.75 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.06, with a Debt / Equity ratio of 0.00.
Current Ratio | 21.06 |
Quick Ratio | 20.72 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.30% and return on invested capital (ROIC) is -22.71%.
Return on Equity (ROE) | -31.30% |
Return on Assets (ROA) | -21.36% |
Return on Invested Capital (ROIC) | -22.71% |
Return on Capital Employed (ROCE) | -38.21% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.53M |
Employee Count | 62 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, ELVN has paid $232,000 in taxes.
Income Tax | 232,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.12% in the last 52 weeks. The beta is 1.10, so ELVN's price volatility has been higher than the market average.
Beta (5Y) | 1.10 |
52-Week Price Change | -33.12% |
50-Day Moving Average | 18.53 |
200-Day Moving Average | 22.43 |
Relative Strength Index (RSI) | 37.79 |
Average Volume (20 Days) | 338,601 |
Short Selling Information
The latest short interest is 6.54 million, so 13.32% of the outstanding shares have been sold short.
Short Interest | 6.54M |
Short Previous Month | 6.96M |
Short % of Shares Out | 13.32% |
Short % of Float | 24.60% |
Short Ratio (days to cover) | 19.97 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -110.26M |
Pretax Income | -79.60M |
Net Income | -94.83M |
EBITDA | -109.95M |
EBIT | -110.26M |
Earnings Per Share (EPS) | -$1.93 |
Full Income Statement Balance Sheet
The company has $289.56 million in cash and $667,000 in debt, giving a net cash position of $288.89 million or $5.89 per share.
Cash & Cash Equivalents | 289.56M |
Total Debt | 667,000 |
Net Cash | 288.89M |
Net Cash Per Share | $5.89 |
Equity (Book Value) | 288.30M |
Book Value Per Share | 5.88 |
Working Capital | 280.35M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$73.96 million and capital expenditures -$44,000, giving a free cash flow of -$74.00 million.
Operating Cash Flow | -73.96M |
Capital Expenditures | -44,000 |
Free Cash Flow | -74.00M |
FCF Per Share | -$1.51 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |